Nerve Injury - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Nerve Injury - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Nerve Injury - Pipeline Review, H2 2014', provides an overview of the Nerve Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nerve Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nerve Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Nerve Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Nerve Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nerve Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nerve Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nerve Injury Overview 7
Therapeutics Development 8
Pipeline Products for Nerve Injury - Overview 8
Pipeline Products for Nerve Injury - Comparative Analysis 9
Nerve Injury - Therapeutics under Development by Companies 10
Nerve Injury - Therapeutics under Investigation by Universities/Institutes 11
Nerve Injury - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nerve Injury - Products under Development by Companies 14
Nerve Injury - Products under Investigation by Universities/Institutes 15
Nerve Injury - Companies Involved in Therapeutics Development 16
Acorda Therapeutics, Inc. 16
Calico LLC 17
Convergence Pharmaceuticals Ltd. 18
F. Hoffmann-La Roche Ltd. 19
Kolon Life Science, Inc. 20
Medtronic, Inc. 21
Neuralstem, Inc. 22
Neurotune AG 23
Pfizer Inc. 24
Nerve Injury - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
3K3A-APC - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cimaglermin alfa - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CLP-257 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CNV-1014802 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
KLS-Nst - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MDT-15 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NSI-566 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NT-1654 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
WAY-258131 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Nerve Injury - Recent Pipeline Updates 49
Nerve Injury - Dormant Projects 58
Nerve Injury - Discontinued Products 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Nerve Injury, H2 2014 8
Number of Products under Development for Nerve Injury - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Nerve Injury - Pipeline by Acorda Therapeutics, Inc., H2 2014 16
Nerve Injury - Pipeline by Calico LLC, H2 2014 17
Nerve Injury - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 18
Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 19
Nerve Injury - Pipeline by Kolon Life Science, Inc., H2 2014 20
Nerve Injury - Pipeline by Medtronic, Inc., H2 2014 21
Nerve Injury - Pipeline by Neuralstem, Inc., H2 2014 22
Nerve Injury - Pipeline by Neurotune AG, H2 2014 23
Nerve Injury - Pipeline by Pfizer Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Nerve Injury Therapeutics - Recent Pipeline Updates, H2 2014 49
Nerve Injury - Dormant Projects, H2 2014 58
Nerve Injury - Discontinued Products, H2 2014 59